{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:30:49Z","timestamp":1780471849552,"version":"3.54.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,8,20]],"date-time":"2015-08-20T00:00:00Z","timestamp":1440028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s11926-015-0541-0","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T08:37:49Z","timestamp":1439973469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Myositis Mimics"],"prefix":"10.1007","volume":"17","author":[{"given":"E. Harlan","family":"Michelle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,20]]},"reference":[{"key":"541_CR1","doi-asserted-by":"crossref","unstructured":"Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. \u00a0JAMA. 2011;305(2):183-90.","DOI":"10.1001\/jama.2010.1977"},{"key":"541_CR2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mus.23302","volume":"45","author":"DE Furst","year":"2012","unstructured":"Furst DE, Amato AA, Iorga SR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012;45:676\u201383.","journal-title":"Muscle Nerve"},{"key":"541_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2474-13-1","volume":"13","author":"KE Smoyer-Tomic","year":"2012","unstructured":"Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord. 2012;13:1\u201313.","journal-title":"BMC Musculoskelet Disord"},{"key":"541_CR4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000369343","volume":"43","author":"A Theadom","year":"2014","unstructured":"Theadom A, Rodrigues M, Roxburgh R, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43:259\u201368.","journal-title":"Neuroepidemiology"},{"key":"541_CR5","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1093\/brain\/awp236","volume":"132","author":"FLM Norwood","year":"2009","unstructured":"Norwood FLM, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175\u201386.","journal-title":"Brain"},{"key":"541_CR6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/s-2008-1062269","volume":"28","author":"M Cardamone","year":"2008","unstructured":"Cardamone M, Darras BT, Ryan MM. Inherited myopathies and muscular dystrophies. Semin Neurol. 2008;28:250\u20139.","journal-title":"Semin Neurol"},{"key":"541_CR7","author":"AD Paltiel","year":"2015","unstructured":"Paltiel AD, Ingvarsson E, Lee DKK, et al. Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve. 2015. doi: 10.1002\/mus.24562 .","journal-title":"Muscle Nerve"},{"key":"541_CR8","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","volume":"134","author":"O Benveniste","year":"2011","unstructured":"Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134:3176\u201384. This study demonstrates that immunosuppressive treatment does not benefit, and may actually harm, patients with IBM.","journal-title":"Brain"},{"key":"541_CR9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nmd.2013.02.010","volume":"23","author":"A Cortese","year":"2013","unstructured":"Cortese A, Machado P, Morrow J, et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord. 2013;23:404\u201312.","journal-title":"Neuromuscul Disord"},{"key":"541_CR10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00401-015-1384-5","volume":"129","author":"O Benveniste","year":"2015","unstructured":"Benveniste O, Stenzel W, Hilton-Jones D, et al. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol. 2015;129:611\u201329.","journal-title":"Acta Neuropathol"},{"key":"541_CR11","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","volume":"134","author":"FM Cox","year":"2011","unstructured":"Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167\u201375.","journal-title":"Brain"},{"key":"541_CR12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ncl.2014.04.001","volume":"32","author":"MM Dimachkie","year":"2014","unstructured":"Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin. 2014;32:629\u201364.","journal-title":"Neurol Clin"},{"issue":"2 Suppl 1","key":"541_CR13","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","volume":"66","author":"RJ Barohn","year":"2006","unstructured":"Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion body myositis. Neurology. 2006;66(2 Suppl 1):S123\u20134.","journal-title":"Neurology"},{"issue":"Pt 6","key":"541_CR14","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","volume":"132","author":"MC Dalakas","year":"2009","unstructured":"Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536\u201344.","journal-title":"Brain"},{"key":"541_CR15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"3","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;3:323\u20137.","journal-title":"Neurology"},{"key":"541_CR16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","volume":"334","author":"ML Kosmidis","year":"2013","unstructured":"Kosmidis ML, Alexopoulos H, Tzioufas AG, et al. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2013;334:123\u20135.","journal-title":"J Neurol Sci"},{"key":"541_CR17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","volume":"63","author":"The Muscle Study Group","year":"2004","unstructured":"The Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology. 2004;63:718\u201320.","journal-title":"Neurology"},{"key":"541_CR18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11926-012-0248-4","volume":"14","author":"H Alexanderson","year":"2012","unstructured":"Alexanderson H. Exercise in inflammatory myopathies, including inclusion body myositis. Curr Rheumatol Rep. 2012;14:244\u201351.","journal-title":"Curr Rheumatol Rep"},{"key":"541_CR19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CND.0b013e3181a23c86","volume":"10","author":"LG Johnson","year":"2009","unstructured":"Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10:178\u201384.","journal-title":"J Clin Neuromuscul Dis"},{"key":"541_CR20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","volume":"70","author":"N Chahin","year":"2008","unstructured":"Chahin N, Engel AG. Correlation of muscle biopsy, clinical course and outcome in PM and sporadic IBM. Neurology. 2008;70:418\u201324.","journal-title":"Neurology"},{"key":"541_CR21","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/nan.12040","volume":"39","author":"F Girolamo","year":"2013","unstructured":"Girolamo F, Lia A, Amati A, et al. Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathol Appl Neurobiol. 2013;39:736\u201349.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"541_CR22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2990.2004.00577.x","volume":"30","author":"CA Maurage","year":"2004","unstructured":"Maurage CA, Bussiere T, Sergeant N, et al. Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Neuropathol Appl Neurobiol. 2004;30:624\u201334.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"541_CR23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00401-009-0511-6","volume":"117","author":"G Vattemi","year":"2009","unstructured":"Vattemi G, Nogalska A, King Engel W, et al. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol. 2009;117:569\u201374.","journal-title":"Acta Neuropathol"},{"key":"541_CR24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2014.08.009","volume":"346","author":"H Hori","year":"2014","unstructured":"Hori H, Yamashita S, Tawara N, et al. Clinical features of Japanese patients with inclusion body myositis. J Neurol Sci. 2014;346:133\u20137.","journal-title":"J Neurol Sci"},{"key":"541_CR25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/ker001","volume":"50","author":"FM Cox","year":"2011","unstructured":"Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology. 2011;50:1153\u20136.","journal-title":"Rheumatology"},{"key":"541_CR26","doi-asserted-by":"crossref","unstructured":"Tasca G, Monforte M, De F, Tasca G, Monforte M, De Fino C, et al. MRI pattern recognition in sporadic inclusion body myositis. Muscle Nerve. 2015. 10.1002\/mus.24661.","DOI":"10.1002\/mus.24661"},{"key":"541_CR27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","volume":"38","author":"RC Griggs","year":"1995","unstructured":"Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38:705\u201313.","journal-title":"Ann Neurol"},{"key":"541_CR28","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","volume":"23","author":"MR Rose","year":"2013","unstructured":"Rose MR, ENMC IBM Working Group. 188th ENMC International Workshop: inclusion body myositis 2\u20134 December, 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013;23:1044\u201355.","journal-title":"Neuromuscul Disord"},{"key":"541_CR29","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2013-305690","volume":"84","author":"S Brady","year":"2013","unstructured":"Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry. 2013;84:1240\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"541_CR30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","volume":"83","author":"TE Lloyd","year":"2014","unstructured":"Lloyd TE, Mammen AL, Amato AA, et al. Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology. 2014;83:426\u201333. This study defines simple, sensitive, and specific diagnostic criteria for IBM.","journal-title":"Neurology"},{"key":"541_CR31","doi-asserted-by":"crossref","unstructured":"Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 5\u2019-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune disease. Ann Rheum Dis. 2015. 10.1136\/annrheumdis-2014-206691.","DOI":"10.1136\/annrheumdis-2014-206691"},{"key":"541_CR32","author":"TE Lloyd","year":"2015","unstructured":"Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5\u2032-nucleotidase 1A is a common target of circulating autoantibodies in several autoimmune diseases. Arthritis Care Res. 2015. doi: 10.1002\/acr.22600 .","journal-title":"Arthritis Care Res"},{"key":"541_CR33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","volume":"73","author":"HB Larman","year":"2013","unstructured":"Larman HB, Salajeghen M, Nazareno R, et al. Cytosolic 5-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73:408\u201318. This study (along with 34) shows that positive anti-NT5C1a testing may be an effective means of distinguishing IBM from PM.","journal-title":"Ann Neurol"},{"key":"541_CR34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","volume":"This study (alo","author":"H Pluk","year":"2013","unstructured":"Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;This study (along with 33) shows that positive anti-NT5C1a testing may be an effective means of distinguishing IBM from PM:397\u2013407. This study (along with 33) shows that positive anti-NT5C1a testing may be an effective means of distinguishing IBM from PM.","journal-title":"Ann Neurol"},{"key":"541_CR35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.5858\/2007-131-1070-MHCCIA","volume":"131","author":"A Jain","year":"2007","unstructured":"Jain A, Sharma MC, Sarka C, et al. Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. Arch Pathol Lab Med. 2007;131:1070\u20136.","journal-title":"Arch Pathol Lab Med"},{"key":"541_CR36","first-page":"136","volume":"75","author":"J Pas van der","year":"2004","unstructured":"van der Pas J, Hengstman GJD, ter Laak HJ, et al. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2004;75:136\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"541_CR37","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.nmd.2014.06.436","volume":"24","author":"PM Rodriguez Cruz","year":"2014","unstructured":"Rodriguez Cruz PM, Luo Y, Miller J, et al. An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies. Neuromuscul Disord. 2014;24:1025\u201335.","journal-title":"Neuromuscul Disord"},{"key":"541_CR38","doi-asserted-by":"crossref","first-page":"e004552","DOI":"10.1136\/bmjopen-2013-004552","volume":"4","author":"S Brady","year":"2014","unstructured":"Brady S, Squier W, Sewry C, et al. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. BMJ Open. 2014;4:e004552. doi: 10.1136\/bmjopen-2013-004552 .","journal-title":"BMJ Open"},{"key":"541_CR39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/2051-5960-1-29","volume":"1","author":"A Hiniker","year":"2013","unstructured":"Hiniker A, Daniels BH, Lee HS, et al. Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun. 2013;1:29\u201342.","journal-title":"Acta Neuropathol Commun"},{"key":"541_CR40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00019052-199910000-00003","volume":"12","author":"RB Fitzsimons","year":"1999","unstructured":"Fitzsimons RB. Facioscapulohumeral muscular dystrophy. Curr Opin Neurol. 1999;12:501\u201311.","journal-title":"Curr Opin Neurol"},{"key":"541_CR41","first-page":"607","volume":"2015","author":"S Sacconi","year":"1852","unstructured":"Sacconi S, Salviati L, Desnuelle C. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta. 1852;2015:607\u201314.","journal-title":"Biochim Biophys Acta"},{"key":"541_CR42","first-page":"556","volume":"2","author":"K Archata","year":"1995","unstructured":"Archata K, Ishihara T, Fukunaga H, et al. Inflammatory response in facioscapulohumeral muscular dystrophy: immunocytochemical and genetic analyses. Muscle Nerve Suppl. 1995;2:556\u201366. Abstract Only.","journal-title":"Muscle Nerve Suppl"},{"key":"541_CR43","author":"JM Statland","year":"2015","unstructured":"Statland JM, Shah B, Henderson D, et al. Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies. Muscle Nerve. 2015. doi: 10.1002\/mus.24621 .","journal-title":"Muscle Nerve"},{"key":"541_CR44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10875-010-9474-6","volume":"31","author":"G Frisullo","year":"2011","unstructured":"Frisullo G, Frusciante R, Nociti V, et al. CD8+ T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol. 2011;31:155\u20136.","journal-title":"J Clin Immunol"},{"key":"541_CR45","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0165-5728(03)00255-8","volume":"142","author":"P Confalonieri","year":"2003","unstructured":"Confalonieri P, Oliva L, Andretta F, et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol. 2003;142:130\u20136.","journal-title":"J Neuroimmunol"},{"key":"541_CR46","doi-asserted-by":"crossref","unstructured":"Amato AA, Brown RF. Dysferlinopathies. In: Amato AA, Griggs RC, editors. Handbook of clinical neurology vol 101. Elsevier Science; 2011. pp. 11-118.","DOI":"10.1016\/B978-0-08-045031-5.00007-4"},{"key":"541_CR47","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1046\/j.1365-2990.2002.00417.x","volume":"28","author":"M Fanin","year":"2002","unstructured":"Fanin M, Angelini C. Muscle pathology in dysferlin deficiency. Neuropathol Appl Neurobiol. 2002;28:461\u201370.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"541_CR48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4103\/0377-4929.81636","volume":"54","author":"N Gayathri","year":"2011","unstructured":"Gayathri N, Alefia R, Nolini A, et al. Dysferlinopathy: spectrum of pathological changes in skeletal muscle tissue. Indian J Pathol Microbiol. 2011;54:350\u20134.","journal-title":"Indian J Pathol Microbiol"},{"key":"541_CR49","unstructured":"Gallardo E, Sienza A, Illa I. LGMD 2A. In: Amato AA, Griggs RC editors. Handbook of clinical neurology vol 101. Elsevier Science; 2011. pp. 101-97."},{"key":"541_CR50","first-page":"148","volume":"32","author":"T Schroder","year":"2013","unstructured":"Schroder T, Fuchss J, Schneider I, et al. Eosinophils in hereditary and inflammatory myopathies. Acta Myol. 2013;32:148\u201353.","journal-title":"Acta Myol"},{"key":"541_CR51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0028-3886.43457","volume":"56","author":"C Sundaram","year":"2008","unstructured":"Sundaram C, Uppin MS, Meero AK. Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. Neurol India. 2008;56:363\u20137.","journal-title":"Neurol India"},{"key":"541_CR52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","volume":"32","author":"M Dasouki","year":"2014","unstructured":"Dasouki M, Jawdat O, Almadhoun O, et al. Pompe disease: literature review and case series. Neurol Clin. 2014;32:751\u201376.","journal-title":"Neurol Clin"},{"key":"541_CR53","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","volume":"128","author":"MLC Hagemans","year":"2005","unstructured":"Hagemans MLC, Winkel LPF, van Doorm PA, et al. Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients. Brain. 2005;128:671\u20137.","journal-title":"Brain"},{"key":"541_CR54","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","volume":"252","author":"LPF Winkel","year":"2005","unstructured":"Winkel LPF, Hagemans MLC, van Doorm PA, et al. The natural course of non-classic Pompe\u2019s disease: a review of 225 published cases. J Neurol. 2005;252:875\u201384.","journal-title":"J Neurol"},{"key":"541_CR55","first-page":"615","volume":"2015","author":"C Angelini","year":"1852","unstructured":"Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. 1852;2015:615\u201321.","journal-title":"Biochim Biophys Acta"},{"key":"541_CR56","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ncpneuro0913","volume":"4","author":"A Lucia","year":"2008","unstructured":"Lucia A, Nogales-Gadea G, Perez M, et al. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008;4:568\u201377.","journal-title":"Nat Clin Pract Neurol"},{"key":"541_CR57","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/jnnp-2011-301593","volume":"83","author":"A Lucia","year":"2012","unstructured":"Lucia A, Ruiz JR, Santalla A, et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012;83:322\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"541_CR58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s13311-013-0188-3","volume":"10","author":"BH Cohen","year":"2013","unstructured":"Cohen BH. Neuromuscular and systemic presentations in adults: diagnoses beyond MERRF and MELAS. Neurotherapeutics. 2013;10:227\u201342.","journal-title":"Neurotherapeutics"},{"key":"541_CR59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2013.07.007","volume":"110","author":"M Milone","year":"2013","unstructured":"Milone M, Wong LJ. Diagnosis of mitochondrial myopathies. Mol Genet Metab. 2013;110:35\u201341.","journal-title":"Mol Genet Metab"},{"key":"541_CR60","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jnnp.68.6.750","volume":"68","author":"RF Duyff","year":"2000","unstructured":"Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry. 2000;68:750\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"541_CR61","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/WNP.0b013e31821c30d9","volume":"28","author":"F Eslamiam","year":"2011","unstructured":"Eslamiam F, Bahrami A, Aghamohammadzadeh N, et al. Electrophysiologic changes in patients with untreated primary hypothyroidism. J Clin Neurophysiol. 2011;28:323\u20138.","journal-title":"J Clin Neurophysiol"},{"key":"541_CR62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000026638","volume":"41","author":"EM Khedr","year":"2000","unstructured":"Khedr EM, El Toony LF, Tarkhan MN, et al. Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings. Neuropsychobiology. 2000;41:88\u201394.","journal-title":"Neuropsychobiology"},{"key":"541_CR63","first-page":"1","volume":"2","author":"J Chowla","year":"2011","unstructured":"Chowla J. Stepwise approach to myopathy in systemic disease. Front Neurol. 2011;2:1\u201310.","journal-title":"Front Neurol"},{"key":"541_CR64","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.rdc.2010.09.001","volume":"36","author":"S Anwar","year":"2010","unstructured":"Anwar S, Gibofsky A. Musculoskeletal manifestations of thyroid disease. Rheum Dis Clin N Am. 2010;36:637\u201346.","journal-title":"Rheum Dis Clin N Am"},{"key":"541_CR65","author":"E Tiniakou","year":"2015","unstructured":"Tiniakou E, Mammen AL. Necrotizing myopathy causes by central hypothyroidism. Muscle Nerve. 2015. doi: 10.1002\/mus.24637 .","journal-title":"Muscle Nerve"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-015-0541-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-015-0541-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-015-0541-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T16:43:51Z","timestamp":1653065031000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-015-0541-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,20]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1007\/s11926-015-0541-0","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,20]]},"article-number":"63"}}